Firing up “cold” tumors: Ferroptosis causes immune activation by improving T cell infiltration

Li, Xinru; Li, Yawen; Tuerxun, Halahati; Zhao, Yixin; Liu, Xingyu; Zhao, Yuguang

doi:10.1016/j.biopha.2024.117298

Biomedicine & Pharmacotherapy

2024

DOI: 10.1016/j.biopha.2024.117298

|View full text |Cite

Firing up “cold” tumors: Ferroptosis causes immune activation by improving T cell infiltration

Xinru Li,

Yawen Li,

Halahati Tuerxun

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Ferroptosis and immunosenescence in colorectal cancer

Wang,

Cao,

Yang

et al. 2024

Seminars in Cancer Biology

View full text Add to dashboard Cite

Ferroptosis and immunosenescence in colorectal cancer

Wang,

Cao,

Yang

et al. 2024

Seminars in Cancer Biology

View full text Add to dashboard Cite

Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors

Catanzaro,

Beltrán-Visiedo,

Galluzzi

et al. 2024

Cell Mol Immunol

View full text Add to dashboard Cite

While immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the clinical management of various malignancies, a large fraction of patients are refractory to ICIs employed as standalone therapeutics, necessitating the development of combinatorial treatment strategies. Immunogenic cell death (ICD) inducers have attracted considerable interest as combinatorial partners for ICIs, at least in part owing to their ability to initiate a tumor-targeting adaptive immune response. However, compared with either approach alone, combinatorial regimens involving ICD inducers and ICIs have not always shown superior clinical activity. Here, we discuss accumulating evidence on the therapeutic interactions between ICD inducers and immunotherapy with ICIs in oncological settings, identify key factors that may explain discrepancies between preclinical and clinical findings, and propose strategies that address existing challenges to increase the efficacy of these combinations in patients with cancer.

show abstract

NSG2: a promising prognostic marker shaping the immune landscape of breast cancer

Li,

Gu,

Sun

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundBreast cancer (BC) remains a significant health issue globally and most common cause of mortality in women. Enhancing our understanding on biomarkers may greatly improve both diagnostic and therapeutic approaches to this disease.MethodsWe retrospectively assessed tumor samples from 228 BC cases and 51 normal samples, alongside relevant clinical data. Neuronal vesicle trafficking associated 2(NSG2) expression was evaluated through bioinformatics and multiplex immunohistochemistry. Associations between NSG2 expression, tumor-infiltrating immune cells (TIICs), immune checkpoints, and clinical outcomes were investigated.ResultsNSG2 was present in both breast cancer cells and adjacent stromal cells. Increased NSG2 expression in cancer cells correlated with greater tumor size, distant metastasis, and more advanced clinical stages. Kaplan-Meier survival and multivariate analyses identified NSG2 expression in both cancer and stromal cells as an independent prognostic factor for breast cancer survival. Elevated NSG2 levels both in cancer and stroma cells were linked to increased CD4+ T, CD8+ T, and Lamp3+ dendritic cells infiltration in stromal regions (P < 0.05). Conversely, the expression of NSG2 in the stroma was negatively correlated with CD20+ B cells (P < 0.05). Additionally, NSG2 expression was found to be associated with CTLA-4 levels (P < 0.05).ConclusionNSG2 seems to be a significant component of the BC immune microenvironment and may serve as an important prognostic marker.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Firing up “cold” tumors: Ferroptosis causes immune activation by improving T cell infiltration

Cited by 3 publications

References 101 publications

Ferroptosis and immunosenescence in colorectal cancer

Ferroptosis and immunosenescence in colorectal cancer

Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors

NSG2: a promising prognostic marker shaping the immune landscape of breast cancer

Contact Info

Product

Resources

About